Peptides vs TRT vs Anabolic Steroids: How They Differ, Side Effects, Monitoring and Testing

TRT is testosterone, the main male sex hormone, prescribed to men whose testes no longer make enough of it. It is a treatment for a diagnosis, hypogonadism, and the threshold is deliberately strict. The approved labels direct confirming the diagnosis with serum testosterone measured in the morning on at least two separate days, both below the normal range. The European Male Ageing Study of 3,369 men aged 40 to 79 found that only three symptoms, poor morning erections, low desire and erectile dysfunction, were tied to low testosterone as a syndrome (New England Journal of Medicine, 2010). The Baltimore Longitudinal Study of Aging found about 20 percent of men over 60 had total testosterone in the hypogonadal range (Journal of Clinical Endocrinology & Metabolism, 2001). Most men over 40 are not hypogonadal.

Testosterone has FDA-approved products with approved labels, and those labels carry a defined monitoring protocol. The dose aims to restore a normal range, not exceed it.

Anabolic steroids are synthetic derivatives of testosterone, built to strengthen its muscle-building (anabolic) effect. They act on the androgen receptor in muscle, the same receptor testosterone uses. Used to build muscle, they are typically taken at doses well above what replacement aims for. Their effect on lean mass in trained people is large and well documented, which is exactly why they are banned in sport and why the side-effect list is long.

Peptides are short chains of amino acids. The ones that get compared with testosterone and steroids fall into three groups, and none of them is an androgen:

• Growth-hormone-axis peptides. Sermorelin, CJC-1295 and tesamorelin are modified versions of growth-hormone-releasing hormone (GHRH). Ipamorelin and hexarelin mimic ghrelin. All of them act on the pituitary to release your own growth hormone in a pulse. Peptides vs HGH explains how that differs from injecting growth hormone itself.
• Kisspeptin. A hormone the body already makes, at the top of the reproductive axis. It prompts GnRH release, which tells the pituitary to release LH and FSH, which drive testosterone production in the testes.
• Repair peptides. BPC-157 and TB-500 are studied around tissue repair. They do not act on any hormone axis.

The body regulates testosterone with a feedback loop. When testosterone from outside raises blood levels, the hypothalamus and pituitary sense it and turn down LH and FSH, and the testes make less of their own. The approved label says so directly: with large doses of external androgens, sperm production may be suppressed through feedback inhibition of pituitary FSH. That is why fertility belongs in any TRT discussion, and why anabolic steroids, at higher doses, suppress the testicular axis further.

They act on a different axis entirely. A GHRH analogue or ghrelin mimetic prompts the pituitary to release growth hormone, which works largely through IGF-1 made by the liver. They do not raise testosterone and are not a testosterone booster. Because the pituitary does the releasing, its own restraining signal (somatostatin) and IGF-1 feedback stay in the circuit. A 2006 study in the Journal of Clinical Endocrinology and Metabolism that sampled growth hormone every ten minutes in adults on CJC-1295 reported that release stayed pulsatile. That feedback is not a ceiling, but it is a structural difference from supplying a hormone.

Kisspeptin is the one peptide here that touches the testosterone system, and it does so from the top rather than by supplying the end product. A 2005 study in the Journal of Clinical Endocrinology and Metabolism reported that intravenous kisspeptin-54 raised LH, FSH and testosterone dose-dependently in healthy men, and a 2011 study in the same journal reported the same for kisspeptin-10 after a single bolus or short infusion. A 2013 study in Clinical Endocrinology reported it in men with type 2 diabetes and mild biochemical hypogonadism.

The limits are important. Every one of those studies was intravenous and measured hours, not months. The response fades with continuous exposure, which is why a kisspeptin schedule is built around gaps. No trial has measured what a subcutaneous kisspeptin-10 course does to testosterone over weeks, and it has not been shown to treat low testosterone. External testosterone suppresses the very system kisspeptin acts on, and nothing supports using them together. Full reference: what is kisspeptin.

A 2022 network meta-analysis in the Journal of Urology pooled 29 placebo-controlled trials in 3,393 men and reported a significant rise in haematocrit with every testosterone formulation studied. The approved labels also note that testosterone can raise blood pressure, that oestradiol rises as some testosterone converts to it, and that prostate evaluation is needed before and during treatment.

Lipids, fertility, cardiovascular effects and mood are the main concerns, on top of everything that applies to testosterone, because the doses used for muscle building are typically higher than replacement.

Mostly local and early. The bigger theme is glucose: growth hormone reduces insulin sensitivity, and the approved tesamorelin label warns glucose intolerance or diabetes may develop. A cancer history is a conversation first wherever growth signalling is involved. See is CJC-1295 / ipamorelin safe and is sermorelin safe.

The human studies, mostly with the longer kisspeptin-54 form, describe it as well tolerated. Repeated subcutaneous kisspeptin-10 over months has not been studied, which is the gap the FDA has flagged. A history of hormone-sensitive cancer must be raised first.

The most relevant human evidence gave recombinant growth hormone, not a peptide. A 26-week randomised, double-blind trial in JAMA in 2002, in 57 women and 74 men aged 65 to 88, compared growth hormone, sex steroid, both, or placebo; lean mass rose most on the combination, strength rose only marginally, and diabetes or glucose intolerance was more common in the growth hormone arms. A 2006 trial in 80 men aged 65 to 80 reported more benefit from low-dose growth hormone with testosterone than from either alone. Neither tested a secretagogue.

A 2008 systematic review in the Annals of Internal Medicine pooled 27 randomised study samples in young, fit adults: growth hormone increased lean body mass, but strength and exercise capacity did not appear to improve, and soft-tissue swelling and fatigue were more common. A 2010 trial in 96 recreational athletes found the lean-mass increase was accounted for by extracellular water. Those trials used injected growth hormone; a secretagogue working through an intact pituitary should be expected to do less.

Tesamorelin has phase 3 trials behind an approved product for visceral fat in HIV-associated lipodystrophy. Sermorelin has randomised studies in older adults. CJC-1295 and ipamorelin have volunteer pharmacology and no outcome trials for recovery or body composition. Kisspeptin has well-mapped human physiology from short intravenous studies, not trials of the product as prescribed. There is no trial comparing any peptide with testosterone or steroids, and none of the compounded peptides is FDA approved. Anyone advertising a secretagogue as producing steroid-like size is not describing the pharmacology. Peptides for muscle growth and recovery goes further.

That is hypogonadism, and the treatment is testosterone under its own monitoring, from your own physician. No peptide substitutes for it, and layering a peptide on untreated hypogonadism produces a monthly bill and a disappointment. Sleep apnoea, weight, alcohol and medications can all lower testosterone, so a single low draw in someone who snores and wakes unrefreshed is not yet a diagnosis. Peptides for men over 40 covers what to rule out first.

This is the person a GH-axis peptide is usually considered for: sermorelin as the gentlest single agent or CJC-1295 / Ipamorelin as the standard pairing, dosed at bedtime when the natural growth hormone pulse is largest. Where the goal is fat around the middle, tesamorelin is the one with that endpoint in its trials.

BPC-157 + TB-500 addresses a different problem from any hormone. There are no human trials of either for tendon or muscle injury; the case is animal research plus prescriber experience.

Kisspeptin is the option that works upstream rather than supplying testosterone, with the caveats above: no evidence it treats hypogonadism, Category 2 status, and not for anyone already on testosterone. If the real issue is desire, kisspeptin vs PT-141 compares the two.

No peptide here does that, and an honest prescriber will say so. Growth-hormone-axis peptides are prescribed for recovery and sleep quality, not size.